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Links & Links, Mexico City, Mexico, 2 Pfizer S.A. de C.V., México City, Mexico OBJECTIVES: Pulmonary arterial hypertension (PAH) is a clinical condition that causes decreased exercise tolerance and heart failure. The aim of this study was to assess the cost-effectiveness of different drugs to manage PAH in adult, functional class III, patients, who have failed previously to calcioantagonists, from the health care payer's perspective. METHODS: A five-state Markov model was performed to estimate one year costs and health consequences (1-month cycles). Effectiveness measures were quality-adjusted life years (QALY's) gained, as well as reduction in hospital length of stay (LOS) and discontinuation rate due to adverse events. Transition probabilities were obtained from a meta-analysis involving national and international published literature. Doses of comparators used in the assessment were sildenafil (60 mg/day); bosentan (250 mg/day); sitaxsentan (100 mg/day) and ambrisentan (5 mg/day, reference alternative). Resource use and costs were obtained from hospital records (n = 110) from the Social Security Mexican Institute. Costs include hospital stay, laboratory and respiratory function tests, imagenology, drugs and adverse events management. The model was validated according to international guidelines. Sensitivity analyses were performed employing bootstrapping techniques and acceptability curves were constructed. RESULTS: Per patient associated costs for sildenafil, bosen-tan, sitaxsentan and ambrisentan were [CI 95%]: US$16, 840 [US$16, 176] , US$38, 068 [US$37, 497] , US$40, 203 [US$39, 647] and US$26, 146 [US$25, 479] , respectively. Sildenafil is associated to the highest gain in QALY's: 0.1 [−0.01-0.22], as well as to the main reduction in discontinuation rate: 89.25 [89.11%-89.4%] and reduction in LOS: 8.64 days [8.53 days-8.75 days], respectively. In consequence, sildenafil represents the most attractive therapy to manage PHA in terms of cost-effectiveness. CONCLUSIONS: In the Mexican institutional setting, sildenafil demonstrated to be a cost-saving therapy to manage PHA in adult, functional class III patients. These results should be taken into account by Mexican health professionals to generate efficient resource allocation strategies. Tables; for deceased patients, only the number of survival days as reported in the CRF, was retained. Per patient survival was then weighed using a predicted death rate based on individual Apache II scores, to account for disease severity. Univariate sensitivity analyses on costs and outcomes and 2000 Bootstrap simulations were run to test CEA's results. RESULTS: Based on the expected number of survival years (PMX-CT 8.24/patient, CT 4.69/patient), the mean difference in survival yielded an expected increase of 3.55LYG/patient for PMX-CT, at the additional cost of 313,411/patient with a mean ICER of 33,774/LYG and a median ICER of 32,776/LYG. Results of the base-case CEA were confirmed by all sensitivity analyses with ICER values always well below commonly accepted value thresholds.CONCLU-SIONS: PMX-CT vs. CT is a cost-effective intervention for treatment of severe abdominal sepsis and septic shock and should be considered for use in the Italian NHS' hospital setting.
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COST-EFFECTIVENESS OF POLYMYXIN B IMMOBILIZED FIBER COLUMN AND CONVENTIONAL MEDICAL THERAPY IN THE MANAGEMENT OF SEVERE ABDOMINAL SEPSIS IN ITALY
CE4 A PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF TARGETED VACCINATION POLICIES TO MITIGATE THE IMPACT OF THE H1N1 PANDEMIC IN THE US
Hettle R, Reason T Heron Evidence Development Ltd, Luton, Bedfordshire, UK OBJECTIVES: Under the circumstances of a severe pandemic and constrained research and manufacturing capacity, the need to appropriately deploy vaccination stockpiles becomes critical. The objective of this study was to provide insight into the most cost-effective vaccination strategy when under constrained circumstances. METHODS: A deterministic and compartmental SIR (Susceptible-Infected-Removed) cost-effectiveness model was developed from a US CDC perspective using Microsoft Excel. The model consists of 6 distinct age groups, integrated by a contact matrix. The infectivity of the pandemic was based on reported CDC estimates, with the model calibrated accordingly. A 75% vaccination efficacy was used, consistent with previous studies. Under the assumption of stockpiling 50 million doses of vaccine, vaccination strategies were assessed in terms of infections avoided during the estimated 17 month period of the pandemic. The scenarios included strategies targeted to specific age groups: individually targeted age groups, groups under 20, over 20, 20-59 and 0-12 and 60+ combined. Costs were limited to vaccine acquisition, with the total rate of vaccination per day estimated at 741,935. For the base case, we initiate the pandemic in May 2009 and began vaccination in October. Sensitivity analysis on the initiation of vaccination was also assessed. RESULTS: With no vaccination, a basic reproduction number of 1.3 and infectious period of 4.5 days yielded an attack rate of 27.7%.The cost-effectiveness of targeted vaccination ranged from $4.87 (13-19 years) to $67.05 (65+) per infection avoided. Under the criteria of exhausting vaccine supplies, the most cost-effective strategy was to target those under 20 years old ($10.77 per infection avoided). Initiating vaccination earlier during a pandemic marginally improved costeffectiveness, while delayed vaccination resulted in substantially reduced cost-effectiveness. CONCLUSIONS: Administering vaccinations to those aged under 20 years is the most cost-effective strategy. All vaccination policies initiated after the peak of the pandemic, were less cost-effective.
